The Treatment of Scabies
A systematic review of randomized controlled trials
; ; ; ;
Background: Scabies is a contagious infestation transmitted by skin-to-skin contact and sometimes by contact with contaminated material. The scabies mite burrows into the skin, producing a papular rash and severe itch at typical sites of predilection.
Methods: We systematically reviewed the literature to compare the efficacy of various anti-scabies agents, including a calculation of relative risks and confidence intervals.
Results: A literature search yielded 596 initial hits; after screening in accordance with the defined inclusion and exclusion criteria, 16 studies were selected for this review. Among topical treatments for scabies, permethrin was equally effective or more effective than crotamiton or benzyl benzoate. In a comparison of topical versus systemic treatment, topical permethrin and systemic ivermectin did not differ substantially in efficacy (7 comparative studies revealed no difference; one revealed a difference in favor of permethrin). Comparative trials of topical benzyl benzoate versus systemic ivermectin yielded inconsistent findings. Single and double administrations of ivermectin were similarly effective. In trials involving entire populations with a high prevalence of scabies, systemic ivermectin was found to be superior to topical permethrin.
Conclusion: There are hardly any differences in efficacy between the available treatments for scabies. Single administrations of permethrin 5%, crotamiton 10%, and systemic ivermectin are all comparably effective. There are differences in the frequeny and ease of application as well as when eradicating scabies in populations with a high prevalence.
Scabies is a common skin disease worldwide, particularly in developing countries. It affects up to 130 million people (1). Increasing migration means that scabies has once again become a more common suspected or confirmed diagnosis in Germany too, at physician practices and emergency departments. Scabies patients’ main symptom is excruciating pruritus, which is usually particularly severe at night (2).
Scabies is transmitted by the female scabies mite, which burrows into the top layer of the epidermis to lay eggs, before dying 30 to 60 days later. After approximately 2 to 3 weeks, sexually mature mites hatch from the eggs (3). This period is important for treatment with substances that are not ovicidal and are not sufficiently stored in the skin. Mites can survive for only approximately 2 days outside the body (4).
In common scabies, the scabies mite is transmitted during sufficiently long-lasting skin-to-skin contact—at least 10 minutes (4). In contrast, for crusted scabies, with millions of mites on the skin, short contact with patients and contaminated materials is sufficient.
If infestation occurs, the first papules appear within 2 to 5 weeks. These are tunnel-shaped or comma-shaped and range in length from a few millimeters to 1 cm. They occur in typical locations where the outer layer of skin is thin, such as the interdigital folds, the areola, the navel region, and, in men, particularly the shaft of the penis. An eczematous reaction with disseminated, mite-free erythematous papules or papular vesicles, causing the characteristic severe pruritus, is a sign of a cell-mediated immune response.
Scratching, encrustation, and possible impetiginization lead to a varied morphological picture over a matter of weeks. This can vary a great deal in severity and can lead to bacterial infections. A further sign of scabies is itching in contact persons. Diagnosis is confirmed using microscopic evidence of mites, eggs, or feces from skin scrapings or on the basis of evidence of mites obtained by dermatoscope (5).
There is an increased risk of outbreaks in facilities in which large numbers of people live in close contact with each other. Care homes for the elderly are particularly affected because older people with multiple morbidities develop crusted scabies more easily as a result of drug-induced or age-related immunosuppression and because care for residents entails more frequent, longer contact.
During major migrations such as are currently being seen, the prevalence of scabies in those seeking refuge is somewhat higher than in the general German population. The risk of outbreaks is low, however, as those affected are immunocompetent, and ordinary contact with other members of the population is insufficient for transmission.
As no immunity develops to scabies, reinfestations are common unless all relevant contact persons, e.g. life partners and relatives, also receive appropriate treatment. In contrast, resistance to the antiscabies drugs detailed below has not yet been described in Germany and is rarely described elsewhere (6).
The current common treatment options in Germany are permethrin 5% topical, benzyl benzoate 10%/25% topical, and crotamiton 5%/10% topical with ivermectin systemic (7). The latter was authorized in Germany and launched on the market in spring 2016 (8). It is easier to use and had already been recommended in the German guideline for crusted scabies and other conditions as early as 2006 (9). Unlike topical treatments with permethrin, for example, it is not ovicidal. However, it accumulates in the epidermis.
This review summarizes the available data on the efficacy of common antiscabies drugs.
A systematic review of the literature was performed to evaluate the available evidence comparing the efficacy and safety of various antiscabies drugs. The review was performed according to the Cochrane Method (10).
Inclusion and exclusion criteria
The review included randomized controlled trials in scabies patients. Trials in which whole populations with a high prevalence of scabies received therapeutic and/or preventive treatment were also included.
Studies comparing topical benzyl benzoate, crotamiton, ivermectin, permethrin, and sulfur as well as systemic ivermectin were included. Placebo-controlled trials and trials that compared different dosage forms were not included (eTable 1).
Three electronic databases (MEDLINE, MEDLINE In-Process, EMBASE [OvidSP], and the Cochrane Library [Wiley]) were searched (search strategy) (eBox).
Two authors (CD, SR) independently screened all identified titles and abstracts for compliance with the inclusions/exclusion criteria. The fulltexts of the selected publications were then evaluated on the basis of the same criteria. Using a standard evaluation sheet (MS Excel 2013), data was extracted by one author (CD) and verified by a second (SR). Differences in opinion were resolved through discussion with the third author (RNW). (Figure).
The data extracted was analyzed using Review Manager (11). For binary variables, relative risk (RR) with a selected confidence interval of 95% (95% CI) was calculated as a measure of treatment effect. Calculation in Review Manager is based on the Mantel–Haenszel (M–H) method.
Trials evaluating the same treatment options were examined for clinical comparability and statistical heterogeneity (I2) in order to consider the possibility of pooling them. Where there was statistical heterogeneity, with I2 of 20% or above, sensitivity analyses were planned. Trials were not pooled if I2 was 80% or above (10).
Evaluation of trials’ methodological quality
The risk of bias was evaluated using the Cochrane Risk of Bias (RoB) Assessment Tool (10). The potential risk of overestimating the effect found in each trial was included in the Discussion.
The literature search performed on 24 November, 2015 yielded 578 hits. 178 duplicates were removed, 400 titles/abstracts were viewed, and 57 fulltexts were examined for compliance with the inclusion and exclusion criteria. A list of the 35 excluded trials, including the reasons for exclusion and references, is provided in eTable 2. The search was last updated on 24 June, 2016 (autoalerts), when a further 32 trials were identified.
Sixteen publications were included in the review (eTable 3). These reported 6 comparisons of different substances, or different frequencies of administration, or different formulations.
An additional 8 trials were also identified. These met the inclusion criteria but are reported separately, as their validity is questionable (eTable 4).
The Table provides a simplified summary of individual comparisons. This includes only the lowest relative risk with a 95% confidence interval and the highest relative risk with a 95% confidence interval for each treatment comparison.
A detailed description of the study results, including findings on safety, as well as selected forest plots can be found in the eMethods section, showing the results of all studies included.
Due to the statistical heterogeneity (I2 greater than 80%) and clinical heterogeneity meant it was only possible to pool the results once. The studies differ from each other in terms of their design, frequency of treatment, and/or in their definition of the outcome parameters (eTable 3).
The following conclusions can be drawn from the comparison of different topical treatments: after 2 weeks a single dose of permethrin was found to be of comparable efficacy to crotamiton, but after 4 weeks, it was superior to crotamiton (12). When administered twice, neither drug was superior after 4 weeks (13).
In comparison of topical ivermectin and topical permethrin, neither was found to be superior.
No difference in efficacy was found between sulfur and benzyl benzoate. The only superiority found was in favor of three-time application of sulfur versus a single application of sulfur; however, possible skin irritation, the aroma of sulfur, and the frequency of application limit its use.
Studies describing 3 comparisons of topical and systemic therapies were also included. A total of 6 trials reported findings after 2 and/or 4 weeks on the efficacy of topical permethrin versus systemic ivermectin. Efficacy was comparable, although the trials differed in terms of their outcome parameter and other factors. Frequency of repeat treatment was inadequately reported.
Five trials investigated the efficacy of topical benzyl benzoate versus systemic ivermectin. Comparison revealed heterogeneous findings, hence no firm conclusion can be drawn (eMethods).
Topical ivermectin was also found to be of comparable efficacy to systemic ivermectin, but only one trial investigating this could be included.
Two trials investigating treatment of mixed populations—confirmed scabies cases and preventive treatment of the unaffected population—were included. No difference was found in terms of the efficacy of various sulfur-containing drugs. In contrast, after 12 months population-based treatment with systemic ivermectin was superior to permethrin as both standard and population-based treatment.
Evaluation of risk of bias
Publication bias cannot be ruled out, as no search was performed to locate unpublished or unregistered trials. No experts were asked about this.
The 16 included trials found little difference in terms of efficacy or tolerability. Crotamiton and permethrin were found to be of similar efficacy, as were topical permethrin and systemic ivermectin. Despite the lack of ovicidal effect of single-dose ivermectin, in most trials efficacy after 2 weeks was comparable to that of single-dose topical ovicidal drugs such as permethrin.
However, there were considerable differences between the included trials in terms of treatment frequency and the definition of the outcome parameters. The comparison of benzyl benzoate and ivermectin, for example, yielded varying findings; this makes it impossible to draw a firm conclusion.
It should be critically noted that one article published in Russian was not included for reasons of cost. This trial and the 8 trials with questionable validity would probably have had no effect, or only a negligible effect, on the overall findings of this review.
The trials included here do not provide an unambiguous answer to the question of whether repeat treatment is needed. There are not enough trials addressing this question; in addition, repeat treatment is often inadequately reported.
In certain conditions repeat treatment should be recommended to ensure that treatment is effective, in order to interrupt a potential chain of infection. Repeat treatment is particularly recommended in cases of crusted scabies, severe scabies with many papules caused by burrows, immunosuppressed patients, doubt as to whether initial treatment was consistently followed, and scabies outbreaks in care homes and situations in which multiple individuals are affected (5).
When large populations with a high prevalence of scabies are treated, systemic ivermectin seems to be superior to topical treatments (26). When large patient groups are treated, the issue of practicability is also significant. Single oral administration of tablets is considerably simpler than professional applications of cream over the whole body. This is also significant in view of the increased risk of reinfestation in residences where space is limited and there is physical contact between individuals.
Treatment of contact persons is important to long-term treatment success (2, 5). The guideline recommends that, as a rule, contact persons such as those in the affected individual’s family or household should also be treated.
The German guideline recommends permethrin for common scabies (5), as it is applied locally and usually only needs to be used once. Based on our findings, no preference can be determined for permethrin or crotamiton in terms of efficacy—crotamiton is a potential alternative, according to our analysis. The guideline recommends it as a pragmatic option for second-line treatment of infants, pregnant women, and breastfeeding women (5). There are no trials in these patient groups. The German guideline recommends that children return to school and adults to work after initial treatment is completed.
Follow-up examinations checking for new-onset efflorescences suggesting scabies should be performed 2 weeks and at least 4 to 6 weeks after treatment (end of mite cycle). Furthermore, treatment should be repeated if there are still signs of active infestation, such as new papules caused by burrows or microscopic or dermatoscopic evidence of live scabies mites, 14 days (or more) after treatment.
Conflict of interest statement
The authors declare that no conflict of interest exists.
Manuscript received on 11 May 2016, revised version accepted on
6 October 2016.
Translated from the original German by Caroline Shimakawa-Devitt, M.A.
Dr. Corinna Dressler, MSc
Division of Evidence-Based Medicine (dEBM)
Klinik für Dermatologie
Charité – Universitätsmedizin Berlin
10117 Berlin, Germany
For eReferences please refer to:
eTables, eFigures, eBoxes, eSupplement:
PD Dr. med. Nast
Department of Dermatology and Venereology, University Hospital Halle:
Prof. Dr. med. Sunderkötter
|1.||World Health Organization: Scabies. www.who.int/lymphatic_filariasis/epidemiology/scabies/en/ (last accessed on 10 March 2016).|
|2.||Wolff HH, Kock S: Ivermectin als orale Einmalbehandlung der Skabies: Das Ende der Lokaltherapie? Dtsch Arztebl 1998; 95: 2095–7 VOLLTEXT|
|3.||Arlian LG, Runyan RA, Estes SA: Cross infestivity of Sarcoptes scabie. J Am Acad Dermatol 1984; 10: 979–86 CrossRef|
|4.||Arlian LG, Runyan RA, Achar S, Estes SA: Survival and infectivity of sarcoptes scabiei var. canis and var. hominis. J Am Acad Dermatol 1984; 11: 210–5 CrossRef|
|5.||Sunderkötter C, Feldmeier H, Fölster-Holst R, et al.: S1-Leitlinie zur Diagnostik und Therapie der Skabies – Kurzfassung. J Dtsch Dermatol Ges 2016 (in press) MEDLINE|
|6.||Mounsey KE, Holt DC, McCarthy J, Currie BJ, Walton SF: Scabies: molecular perspectives and therapeutic implications in the face of emerging drug resistance. Future Microbiol 2008; 3: 57–66 CrossRef MEDLINE|
|7.||Robert-Koch-Institute: Skabies (Krätze), RKI-Ratgeber für Ärzte www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Skabies.html#doc2374546bodyText10 (last accessed on 3 April 2016).|
|8.||Tabassam SM, Iqbal Z, Jabbar A, Sindhu ZU, Chattha AI: Efficacy of crude neem seed kernel extracts against natural infestation of sarcoptes scabiei var. ovis. J Ethnopharmacol 2008; 115: 284–7 CrossRef MEDLINE|
|9.||Sunderkötter C, Mayser P, Fölster-Holst R, Maier W, Kampen H, Hamm H: Therapie der Skabies. Leitlinie der Deutschen Dermatologischen Gesellschaft. J Dtsch Dermatol Ges 2006; 5: 424–30 CrossRef MEDLINE|
|10.||Higgins JPT, Green S, Cochrane Colloboration: Cochrane handbook for systematic reviews of interventions. www.cochrane-handbook.org/ (last accessed on 9 June 2016).|
|11.||Review Manager (RevMan). Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration 2014.|
|12.||Taplin D, Meinking TL, Chen JA, Sanchez R: Comparison of crotamiton 10% cream (Eurax) and permethrin 5% cream (Elimite) for the treatment of scabies in children. Pediatr Dermatol 1990; 7: 67–73 CrossRef|
|13.||Amer M, el-Gharib I: Permethrin versus crotamiton and lindane in the treatment of scabies. Int J Dermatol 1992; 31: 357–8 CrossRef|
|14.||Chhaiya SB, Patel VJ, Dave JN, Mehta DS, Shah HA: Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol 2012; 78: 605–10 CrossRef MEDLINE|
|15.||Gulati PV, Singh KP: A family based study on the treatment of scabies with benzyl benzoate and sulphur ointment. Indian J Dermatol Venereol Leprol 1978; 44: 269–73.|
|16.||Sharquie KE, Al-Rawi JR, Noaimi AA, Al-Hassany HM: Treatment of scabies using 8% and 10% topical sulfur ointment in different regimens of application. J Drugs Dermatol 2012; 11: 357–64 MEDLINE|
|17.||Bachewar NP, Thawani VR, Mali SN, Gharpure KJ, Shingade VP, Dakhale GN: Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies. Indian J Pharmacol 2009; 41: 9–14 CrossRef MEDLINE PubMed Central|
|18.||Mushtaq A, Khurshid K, Suhail Pal S: Comparison of efficacy and safety of oral ivermectin with topical permethrin in treatment of scabies. J Pak Assoc Derma 2010; 20: 227–31.|
|19.||Saqib M, Malik LM, Jahangir M: A comparison of efficacy of single topical permethrin and single oral ivermectin in the treatment of scabies. J Pak Assoc Derma 2012; 22: 45–9.|
|20.||Sharma R, Singal A: Topical permethrin and oral ivermectin in the management of scabies: a prospective, randomized, double blind, controlled study. Indian J Dermatol Venereol Leprol 2011; 77: 581–6 CrossRef MEDLINE|
|21.||Usha V, Gopalakrishnan Nair TV: A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000; 42: 236–40 CrossRef|
|22.||Nnoruka EN, Agu CE: Successful treatment of scabies with oral ivermectin in Nigeria. Trop Doct 2001; 31: 15–8 MEDLINE|
|23.||Glaziou P, Cartel JL, Alzieu P, Briot C, Moulia-Pelat JP, Martin PM: Comparison of ivermectin and benzyl benzoate for treatment of scabies. Trop Med Parasitol 1993; 44: 331–2 MEDLINE|
|24.||Brooks PA, Grace RF: Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. J Paediatr Child H 2002; 38: 401–4 CrossRef|
|25.||Ly F, Caumes E, Ndaw CA, Ndiaye B, Mahe A: Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial. Bull World Health Organ 2009; 87: 424–30 CrossRef PubMed Central|
|26.||Romani L, Whitfeld MJ, Koroivueta J, et al.: Mass drug administration for scabies control in a population with endemic disease. New Engl J Med 2015; 373: 2305–13 CrossRef MEDLINE|
|27.||Avila-Romay A, Alvarez-Franco M, Ruiz-Maldonado R: Therapeutic efficacy, secondary effects, and patient acceptability of 10% sulfur in either pork fat or cold cream for the treatment of scabies. Pediatr Dermatol 1991; 8: 64–6 CrossRef|
|e1.||Abstracts—New Zealand dermatological society incorporated annual scientific meeting. Australas J Dermatol 2009; 50.|
|e2.||Abedin S, Narang M, Gandhi V, Narang S: Efficacy of permethrin cream and oral ivermectin in treatment of scabies. Indian J Pediatr 2007; 74: 915–6 CrossRef|
|e3.||Alrawashdeh B, Alazab K: Comparison between 25% benzyl benzoate, 5% permethrin and 10% crotamiton in the treatment of scabies in Gaza. RMJ 2013; 38: 125–6.|
|e4.||Amerio P, Capizzi R, Milani M: Efficacy and tolerability of natural synergised pyrethrins in a new thermo labile foam formulation in topical treatment of scabies: a prospective, randomised, investigator-blinded, comparative trial vs. permethrin cream. Eur J Dermatol 2003; 13: 69–71 MEDLINE|
|e5.||Asad F, Khan M, Samdani A, Alam R, Rizvi F: To study therapeutic effect and benefit on quality of life in scabies patients. Medical Forum Monthly 2011; 22: 34–7.|
|e6.||Asad F, Rizvi F, Iqbal J: Beneficial effect and safety of 5% permethrin cream in scabies patients. Medical Forum Monthly 2014; 25: 18–21.|
|e7.||Ayaz S, Hannan A, Usmanghani K, et al.: ScaNeem: herbo-mineral therapy for scabies. J Med Plant Res 2011; 5: 5706–12.|
|e8.||Azulay RD, Marinho DEA, Lapolli N, Pola LBP: Topical thiabendazole in the treatment of scabies. Double blind trial in comparison with benzyl benzoate. [Portuguese]. Rev Bras Med 1975; 32: 800–2.|
|e9.||Banez JA, Nazareno RC, Medel RB: Clinical trial on the effectiveness of gliricidia sepium (kakawate) in treating patients with scabies in the antipolo CBHP. Phil J Microbiol Infect Dis 1999; 28: 115–324.|
|e10.||Biele M, Campori G, Colombo R, et al.: Efficacy and tolerability of a new synergized pyrethrins thermofobic foam in comparison with benzyl benzoate in the treatment of scabies in convicts: the ISAC study (Studio Della scabbia in ambiente carcerario). J Eur Acad Dermatol Venereol 2006; 20: 717–20 CrossRef MEDLINE|
|e11.||Burgess I, Robinson RJ, Robinson J, Maunder JW, Hassan Z: Aqueous malathion 0.5% as a scabicide: clinical trial. BMJ 1986; 292: 1172 CrossRef MEDLINE PubMed Central|
|e12.||Camasmie Curiati WJ: Double-blind study with decamethrin in scabies and head louse. [Portuguese]. Rev Bras Med 1984; 41: 81–3.|
|e13.||Castillo AL, Osi MO, Ramos JDA, De Francia JL, Dujunco MU, Quilala PF: Efficacy and safety of tinospora cordifolia lotion in sarcoptes scabiei var hominis-infected pediatric patients: a single blind, randomized controlled trial. J Pharmacol Pharmacother 2013; 4: 39–46 CrossRef MEDLINE PubMed Central|
|e14.||Daneshpajooh M: The comparison of oral ivermectin and topical gamma-benzene hexachloride 1% in treatment of scabies (Persian). Iran J Dermatol 1999; 3: 3.|
|e15.||Dourmishev A, Serafimova D, Dourmishev L: Efficacy and tolerance of oral ivermectin in scabies. J Eur Acad Dermatol Venereol 1998; 11: 247–51 CrossRef|
|e16.||Goldust M, Rezaee E, Raghifar R, Hemayat S: Comparing the efficacy of oral ivermectin vs malathion 0.5% lotion for the treatment of scabies. SKINmed 2014; 12: 284–7 MEDLINE|
|e17.||Goldust M, Rezaee E, Raghifar R, Naghavi-Behzad M: Comparison of permethrin 2.5 % cream vs. tenutex emulsion for the treatment of scabies. Ann Parasitol 2013; 59: 31–5 MEDLINE|
|e18.||Gupta LC, Gupta SR, Sahu UC: Scabies: Survey and clinical trial. Indian J Dermatol 1981; 26: 33–5 MEDLINE|
|e19.||Henderson CA, Nykia M: Treatment of scabies in rural east Africa? A comparative study of two regimens. Trop Doct 1992; 22: 165–7 MEDLINE|
|e20.||Kenawi MZ, Morsy TA, Abdalla KF, Hady HM: Treatment of human scabies by sulfur and permethrin. J-Egypt-Soc-Parasitol 1993; 23: 691–6 MEDLINE|
|e21.||Landegren J, Borglund E, Storgards K: Treatment of scabies with disulfiram and benzyl benzoate emulsion: a controlled study. Acta Derm Venereol 1979; 59: 274–6 MEDLINE|
|e22.||Mohamed A, Ibrahim G: Permethrin versus crotamiton and lindane in the treatment of scabies [abstract no:2]. Indian J Dermatol Venereol Leprol 1993; 58: 301.|
|e23.||Mozgunov VN, Klimenko AV: [Effectiveness of preparations used in treating scabies]. Voen Med Zh 1978: 74.|
|e24.||Neto VS: Comparative study of monosulfiram and benzyl benzoate in the treatment of scabies. Anais Brasileiros de Dermatologia 1984; 59: 213–4.|
|e25.||Oladimeji FA, Orafidiya LO, Ogunniyi TAB, Adewunmi TA, Onayemi O: A comparative study of the scabicidal activities of formulations of essential oil of lippia multiflora moldenke and benzyl benzoate emulsion BP. International Journal of Aromatherapy 2005; 15: 87–93 CrossRef|
|e26.||Oyelami OA, Onayemi A, Oyedeji OA, Adeyemi LA: Preliminary study of effectiveness of aloe vera in scabies treatment. Phytother Res 2009; 23: 1482–4 CrossRef MEDLINE|
|e27.||Panja RK, Choudhury S: A clinical trial with gamma benzene hexachloride in scabies. Indian J Dermatol 1969; 14: 136–7 MEDLINE|
|e28.||Rahman J, Farooqi AH, Sultana A, Rahman K, Rahman A: Clinical efficacy of a herbo-mineral unani formulation in scabies: an open-label randomized controlled study. Orient Pharm Exp Med 2015; 15: 173–81 CrossRef|
|e29.||Rohatgi V, Narayana Reddy S, Vagge DS: A prospective, randomized, open labelled, comparative study of efficacy and cost effectiveness of permethrin and ivermectin in 5–15 years age group patients with scabies in a tertiary care hospital. Indian J Pharmacol 2013; 45: 45.|
|e30.||Saeedi M, Hajheydari Z, Akbari J, Morteza-Semnani K, Emadian A: Preparation of malathion 0.5% lotion and studying its effect on healing scabies compared with permethrin cream 5%. [Persian]. Journal of Mazandaran University of Medical Sciences 2015; 25: 128–31.|
|e31.||Schenone H, Prieto R, Lobos M, Fabres P, Boresi R: Treatment of scabies with a dermatological lotion of decamethrin at 0.02%. Study of 127 patients using 2 therapeutic regimens. [Tratamiento de la sarna con locion dermatologica de decametrine al 0,02%. Estudio en 127 pacientes mediante la utilizacion de dos esquemas terapeuticos]. Bol Chil Parasitol 1986; 41: 3–7 MEDLINE|
|e32.||Srinivas CR, Sathish PB, Sukumar J: Treatment of scabies with 1% gamma benzene hexachloride. Efficacy of drug delivery by bath, spray and painbrush. Indian J Dermatol 1996: 51–2.|
|e33.||Sule HM, Thacher TD: Comparison of ivermectin and benzyl benzoate lotion for scabies in Nigerian patients. Am J Trop Med Hyg 2007; 76: 392–5 MEDLINE|
|e34.||Tausch I: Crotamiton—An effective and safe drug for the treatment of scabies. Results of a controlled clinical trial. [German]. Z Hautkr 1999; 74: 162–6.|
|e35.||Wankhade PA, Tamboli SB, Rathod P, Deshmukh JB, Shirure PA, Ghadlinge MS: Comparison of safety, efficacy, cost effectiveness of permethrin and ivermectin in patients of scabies. Indian J Pharmacol 2013; 45: 202 MEDLINE PubMed Central|
|e36.||Amer M, el-Gharib I: Permethrin versus crotamiton and lindane in the treatment of scabies. Int J Dermatol 1992; 31: 357–8 CrossRef|
|e37.||Taplin D, Meinking TL, Chen JA, Sanchez R: Comparison of crotamiton 10% cream (Eurax) and permethrin 5% cream (Elimite) for the treatment of scabies in children. Pediatr Dermatol 1990; 7: 67–73 CrossRef|
|e38.||Bachewar NP, Thawani VR, Mali SN, Gharpure KJ, Shingade VP, Dakhale GN: Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies. Indian J Pharmacol 2009; 41: 9–14 CrossRef MEDLINE PubMed Central|
|e39.||Chhaiya SB, Patel VJ, Dave JN, Mehta DS, Shah HA: Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol 2012; 78: 605–10 CrossRef MEDLINE|
|e40.||Usha V, Gopalakrishnan Nair TV: A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000; 42: 236–40 CrossRef|
|e41.||Mushtaq A, Khurshid K, Suhail Pal S: Comparison of efficacy and safety of oral ivermectin with topical permethrin in treatment of scabies. J Pak Assoc Derma 2010; 20: 227–31.|
|e42.||Sharma VK, Khandpur S: Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris. Clin Exp Dermatol 2013; 38: 659–64 CrossRef MEDLINE|
|e43.||Sharma R, Singal A: Topical permethrin and oral ivermectin in the management of scabies: a prospective, randomized, double blind, controlled study. Indian J Dermatol Venereol Leprol 2011; 77: 581–6 CrossRef MEDLINE|
|e44.||Ly F, Caumes E, Ndaw CA, Ndiaye B, Mahe A: Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial. Bull World Health Organ 2009; 87: 424–30 CrossRef PubMed Central|
|e45.||Nnoruka EN, Agu CE: Successful treatment of scabies with oral ivermectin in Nigeria. Trop Doct 2001; 31: 15–8 MEDLINE|
|e46.||Brooks PA, Grace RF: Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. J Paediatr Child H 2002; 38: 401–4 CrossRef|
|e47.||Glaziou P, Cartel JL, Alzieu P, Briot C, Moulia-Pelat JP, Martin PM: Comparison of ivermectin and benzyl benzoate for treatment of scabies. Trop Med Parasitol 1993; 44: 331–2 MEDLINE|
|e48.||Gulati PV, Singh KP: A family based study on the treatment of scabies with benzyl benzoate and sulphur ointment. Indian J Dermatol Venereol Leprol 1978; 44: 269–73.|
|e49.||Sharquie KE, Al-Rawi JR, Noaimi AA, Al-Hassany HM: Treatment of scabies using 8% and 10% topical sulfur ointment in different regimens of application. J Drugs Dermatol 2012; 11: 357–64 MEDLINE|
|e50.||Avila-Romay A, Alvarez-Franco M, Ruiz-Maldonado R: Therapeutic efficacy, secondary effects, and patient acceptability of 10% sulfur in either pork fat or cold cream for the treatment of scabies. Pediatr Dermatol 1991; 8: 64–6 CrossRef|
|e51.||Romani L, Whitfeld MJ, Koroivueta J, et al.: Mass drug administration for scabies control in a population with endemic disease. N Engl J Med 2015; 373: 2305–13 CrossRef MEDLINE|
|e52.||Pourhasan A, Goldust M, Rezaee E: Treatment of scabies, permethrin 5% cream vs. crotamiton 10% cream. Ann Parasitol 2013; 59: 143–7 MEDLINE|
|e53.||Goldust M, Rezaee E, Hemayat S: Treatment of scabies: Comparison of permethrin 5% versus ivermectin. J Dermatol 2012; 39: 545–7 CrossRef MEDLINE|
|e54.||Ranjkesh MR, Naghili B, Goldust M, Rezaee E: The efficacy of permethrin 5% vs. oral ivermectin for the treatment of scabies. Ann Parasitol 2013; 59: 189–94 MEDLINE|
|e55.||Goldust M, Rezaee E, Raghifar R, Hemayat S: Treatment of scabies: the topical ivermectin vs. permethrin 2.5% cream. Ann Parasitol 2013; 59: 79–84 MEDLINE|
|e56.||Goldust M, Rezaee E, Raghiafar R: Topical ivermectin versus crotamiton cream 10% for the treatment of scabies. Int J Dermatol 2014; 53: 904–8 CrossRef MEDLINE|
|e57.||Goldust M, Rezaee E, Raghifar R: Comparison of oral ivermectin versus crotamiton 10% cream in the treatment of scabies. Cutan Ocul Toxicol 2014; 33: 333–6 CrossRef MEDLINE|
|e58.||Goldust M, Rezaee E: Comparative trial of oral ivermectin versus sulfur 8% ointment for the treatment of scabies. J Cutan Med Surg 2013; 17: 299–300 MEDLINE|
|e59.||Alipour H, Goldust M: The efficacy of oral ivermectin vs. sulfur 10% ointment for the treatment of scabies. Ann Parasitol 2015; 61: 79–84 MEDLINE|